Summarized by Daily Strand AI from peer-reviewed source
A miniature wireless device implanted in the eye is showing remarkable results for people who have lost their central vision to advanced age-related macular degeneration, the leading cause of blindness in older adults. Macular degeneration damages the macula, the part of the retina responsible for sharp, straight-ahead vision used for reading, recognizing faces, and driving. When those light-sensing cells break down, the eye can no longer convert images into signals the brain can understand. The new implant, no larger than a tiny square measuring 2 by 2 millimeters, steps in to do that job artificially, capturing incoming light and translating it into electrical signals that travel along existing nerve pathways to the brain. In an international clinical trial, more than 80% of participants regained what researchers describe as meaningful central vision after receiving the device. Some patients who had experienced years of steady vision loss were able to read individual letters and even full words again.
Age-related macular degeneration affects tens of millions of people worldwide, and for those with advanced forms of the disease, there are currently very few effective treatment options. A device that could restore functional vision to the majority of patients who receive it would represent a significant shift in what is possible for this population. The ability to read again, even partially, can dramatically change a person's independence and quality of life. That said, important details about this trial, including how many patients participated and how long they were followed after surgery, are not yet publicly reported, so these results should be viewed as promising but preliminary. Larger, longer studies will be needed before the full picture of safety, durability, and effectiveness becomes clear.
Interested in Neurotech?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.